Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Relmada Therapeutics Inc.
Fiscal year is September-August. All values USD millions. 2012 2013 5-year trend
Sales/Revenue - - - 7,941 5,129
Cost of Goods Sold (COGS) incl. D&A - - - 5,799 4,036
COGS excluding D&A - - - 5,799 3,786
Depreciation & Amortization Expense - - - 0 250
Depreciation - - - 0 250
Amortization of Intangibles - - - 0 0
Gross Income - - - 2,142 1,093
2012 2013 5-year trend
SG&A Expense - - - 13,817 46,108
Research & Development - - - - -
Other SG&A - - - 13,817 46,108
Other Operating Expense - - - 377 0
Unusual Expense - - - 0 0
EBIT after Unusual Expense - - - 0 0
Non Operating Income/Expense - - - 0 0
Non-Operating Interest Income - - - - -
Equity in Affiliates (Pretax) - - - 0 0
Interest Expense - - - 0 0
Gross Interest Expense - - - 0 0
Interest Capitalized - - - 0 0
Pretax Income - - - (12,052) (45,015)
Income Tax - - - 0 0
Income Tax - Current Domestic - - - 0 0
Income Tax - Current Foreign - - - 0 0
Income Tax - Deferred Domestic - - - 0 0
Income Tax - Deferred Foreign - - - 0 0
Income Tax Credits - - - 0 0
Equity in Affiliates - - - 0 0
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income - - - (12,052) (45,015)
Minority Interest Expense - - - 0 0
Net Income - - - (12,052) (45,015)
Extraordinaries & Discontinued Operations - - - 0 0
Extra Items & Gain/Loss Sale Of Assets - - - 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations - - - 0 0
Net Income After Extraordinaries - - - (12,052) (45,015)
Preferred Dividends - - - 0 0
Net Income Available to Common - - - (12,052) (45,015)
EPS (Basic) - - - () ()
Basic Shares Outstanding - - - 16.31M 24.33M
EPS (Diluted) - - - () ()
Diluted Shares Outstanding - - - 16.31M 24.33M
EBITDA - - - (12,052) (44,765)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.